Anuh Pharma Ltd Q3 FY22 Earnings Call Analysis
Revenue, margin, capex, fundraise and order book outlook from management commentary.
Management growth scorecard
Revenue
Category 2
Margin
Category 3
Fundraise
N/A
Order
N/A
Capex
Yes
1 of 3 growth signals are positive — mixed outlook.
Full analysisRevenue guidance
Category 2- →The company targets a revenue of Rs. 800 crores in the next five years, aiming for a 15% year-on-year growth.
- →For the financial year 2022, the anticipated total revenue is around Rs. 565 crores, with confidence to achieve this target despite COVID-related demand fluctuations.
- →The top-line for financial year 2023 is expected to reach Rs. 600 crores, reflecting continued growth.
- →Quarterly manufacturing turnover expectations include approximately Rs. 130-140 crores in Q4 and Rs. 190 crores mentioned for some quarters, indicating varying projections.
- →The company plans to launch at least five new products annually to expand its market share.
- →Backward integration efforts are ongoing to reduce reliance on imports and improve margins.
- →The focus is on organic growth and capital expenditure on capacity expansions to support sales volume increases.
See what Anuh Pharma Ltd management said on margin guidance — free account, 30 seconds.
Fundraise plans
- →There is no mention of any current or planned new fundraising through debt or equity in the transcript.
- →The company is focused on organic growth and is exploring suitable business expansion opportunities.
- →The management has not indicated any intentions regarding fresh capital raising.
- →The primary financial discussions revolve around revenue growth, profitability, NSE listing, and operational matters, with no references to debt or equity fundraising activities.
See what Anuh Pharma Ltd management said on order book — free account, 30 seconds.
Capex plans
Yes- →The transcript does not explicitly mention any detailed ongoing or planned capital expenditure (capex) or strategic investments.
- →There is a reference to capacity utilization at 17% on an expanded capacity in FY20, indicating potential room for future capex to increase utilization.
- →The company is focused on backward integration in some products, such as manufacturing raw material DCMP for sulfadoxine, which suggests ongoing strategic manufacturing investments.
- →Management highlights efforts toward cost reduction and operating efficiency, implying indirect investments in process improvement rather than explicit large capex.
- →No specific figures, timelines, or upcoming project announcements related to capital or strategic investments are disclosed in the provided pages.
Track Anuh Pharma Ltd — get its next earnings analysis in your feed
Margin guidance
Category 3- →For the financial year 2022 (FY22), Anuh Pharma anticipates:
- → - Total revenue (top line) of approximately Rs. 565 crores, reflecting around 30% growth from Rs. 432 crores in the previous year.
- → - EBITDA margin calibrated to around 10%, revised down from earlier estimates of 12-15% due to product mix changes and cost escalations.
- → - EBITDA expected to be around Rs. 50 crores by March 2022.
- →For the financial year 2023 (FY23):
- → - Top line target set at Rs. 600 crores.
- → - EBITDA target of Rs. 67 crores.
- →Margins are expected to be between 10-12% pessimistically for EBITDA.
- →Net profit targets are less definitive due to factors like mark-to-market fluctuations.
- →The company is confident of achieving these targets despite market and COVID-19 demand volatility.
Order book
How does Anuh Pharma Ltd rank vs peers in Pharmaceuticals & Biotechnology?
Pro featureSee full Pharmaceuticals & Biotechnology sector rankings
How does Anuh Pharma Ltd rank in Pharmaceuticals & Biotechnology?
Compare Anuh Pharma Ltd against every Pharmaceuticals & Biotechnology company (Q3 FY22) on revenue, margins and earnings-call signals.
Continue your research
What Anuh Pharma Ltd's management said in earlier quarters
Others in Pharmaceuticals & Biotechnology this season
- IOL Chemicals (Q1 FY27)
Expansion plans supported by capex of INR 200-250 crores annually, with 60% towards expansion/new products and 40% towards efficiency improvements. Key concall…
- Innova Captab (Q1 FY27)
The company is confident of achieving 20%+ volume growth backed by steady ramp-up in Jammu and existing facilities. Key concall takeaways from Innova Captab…
- Glenmark Pharma. (Q1 FY27)
Chronic respiratory segment in India showing over 25% growth; oncology and cardiovascular segments also strong. Key concall takeaways from Glenmark…
- Strides Pharma (Q1 FY27)
markets continue to be broad-based growth drivers, with 17% YoY growth and expansion in B2B and B2C markets including Europe, UK, Nordics, Africa, LATAM, MENA…